Nonbiological factors, or factors not related to a disease, were found to independently affect the survival of younger patients with acute myeloid leukemia (AML). Specifically, researchers found that insurance status, marital status, and county-level income affected short- and long-term mortality of these patients, according to a study published in Cancer.
“We believe these three factors indicate lack of material and social support preventing young patients from successfully walking the long and difficult road towards a cure,” said lead author Uma Borate, MD, assistant professor in the division of hematology and oncology at the University of Alabama at Birmingham, in a prepared statement.
Borate and colleagues looked at 5,541 patients age 19 to 64 years diagnosed with AML between 2007 and 2011 taken from the Surveillance, Epidemiology, and End Results (SEER) registry. They examined nonbiological factors including marital status, insurance status, and county-level income and education, as well as biological factors, to assess their effect on survival.
The median overall survival of the cohort was 16 months. When the researchers conducted a multivariate analysis, they found that insurance status, marital status, and county-level median household income were all independently associated with survival.
Patients without health insurance or those with Medicaid had a median survival of 13 months compared with 17 months for patients with private insurance. Single and married patients had a median survival of 16 months compared with 13 months for divorced patients and 10 months for widowed patients. Finally, patients in counties with a median household income in the first, second, or third quintile had a median survival of 14 months compared with 17 and 22 months for the fourth and fifth quintile, respectively.
“An increased risk of death was independently linked to being a Medicaid beneficiary, uninsured, single, or divorced or residing in a county with a median household income in the lower three quintiles,” the researchers wrote. “Education and distance to an HSCT [hematopoietic stem cell transplantation] center did not appear to independently predict survival.”
The study also showed that these three factors affected both early and late mortality, and the researchers confirmed this effect among patients known to have received chemotherapy (88.7% of the cohort).
“Health care professionals and institutions caring for patients with AML should be able to identify socially vulnerable patients who may benefit from additional resources and support during their therapy,” the researchers concluded. “Future research should focus on mechanisms by which nonbiological factors negatively affect the outcomes of younger patients with AML and develop tools to minimize their impact.”
Social Factors Affected Survival of Young Patients With AML
Nonbiological factors such as insurance and marital status and county-level income were found to independently affect the survival of younger patients with AML.
Nonbiological factors, or factors not related to a disease, were found to independently affect the survival of younger patients with acute myeloid leukemia (AML). Specifically, researchers found that insurance status, marital status, and county-level income affected short- and long-term mortality of these patients, according to a study published in Cancer.
“We believe these three factors indicate lack of material and social support preventing young patients from successfully walking the long and difficult road towards a cure,” said lead author Uma Borate, MD, assistant professor in the division of hematology and oncology at the University of Alabama at Birmingham, in a prepared statement.
Borate and colleagues looked at 5,541 patients age 19 to 64 years diagnosed with AML between 2007 and 2011 taken from the Surveillance, Epidemiology, and End Results (SEER) registry. They examined nonbiological factors including marital status, insurance status, and county-level income and education, as well as biological factors, to assess their effect on survival.
The median overall survival of the cohort was 16 months. When the researchers conducted a multivariate analysis, they found that insurance status, marital status, and county-level median household income were all independently associated with survival.
Patients without health insurance or those with Medicaid had a median survival of 13 months compared with 17 months for patients with private insurance. Single and married patients had a median survival of 16 months compared with 13 months for divorced patients and 10 months for widowed patients. Finally, patients in counties with a median household income in the first, second, or third quintile had a median survival of 14 months compared with 17 and 22 months for the fourth and fifth quintile, respectively.
“An increased risk of death was independently linked to being a Medicaid beneficiary, uninsured, single, or divorced or residing in a county with a median household income in the lower three quintiles,” the researchers wrote. “Education and distance to an HSCT [hematopoietic stem cell transplantation] center did not appear to independently predict survival.”
The study also showed that these three factors affected both early and late mortality, and the researchers confirmed this effect among patients known to have received chemotherapy (88.7% of the cohort).
“Health care professionals and institutions caring for patients with AML should be able to identify socially vulnerable patients who may benefit from additional resources and support during their therapy,” the researchers concluded. “Future research should focus on mechanisms by which nonbiological factors negatively affect the outcomes of younger patients with AML and develop tools to minimize their impact.”
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
FDA ODAC Votes 8-to-1 Against Applicability of Glofitamab DLBCL Data
The FDA’s ODAC convened to discuss the potentially inconsistent treatment effects of glofitamab between regional subgroups in the phase 3 STARGLO trial.
Highlighting Advancements in Personalized T-Cell Lymphoma Treatment
Advances in next-generation sequencing and gene expression are reshaping T-cell lymphoma classification and the use of targeted therapies.
Addressing Real-World Use of Liso-Cel vs Axi-Cel in DLBCL
CAR T-cell therapies such as liso-cel and axi-cel in DLBCL were the focal points during an Around the Practice program at the 2025 Tandem Meeting.
Reviewing Real-World Use of Beti-Cel in Transfusion-Dependent β-Thalassemia
Therapies such as betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.
Loncastuximab Tesirine Combo Demonstrates Early Efficacy in R/R DLBCL
The safety profile of loncastuximab tesirine plus glofitamab was consistent with the known profiles of the individual agents.
Rare Primary ALK-Positive Anaplastic Large Cell Lymphoma of the Central Nervous System
Anaplastic large cell lymphoma is a rapidly growing and aggressive hematological malignancy. This case highlights the rarity of isolated intradural extramedullary manifestations in the pediatric population.
FDA ODAC Votes 8-to-1 Against Applicability of Glofitamab DLBCL Data
The FDA’s ODAC convened to discuss the potentially inconsistent treatment effects of glofitamab between regional subgroups in the phase 3 STARGLO trial.
Highlighting Advancements in Personalized T-Cell Lymphoma Treatment
Advances in next-generation sequencing and gene expression are reshaping T-cell lymphoma classification and the use of targeted therapies.
Addressing Real-World Use of Liso-Cel vs Axi-Cel in DLBCL
CAR T-cell therapies such as liso-cel and axi-cel in DLBCL were the focal points during an Around the Practice program at the 2025 Tandem Meeting.
Reviewing Real-World Use of Beti-Cel in Transfusion-Dependent β-Thalassemia
Therapies such as betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.
Loncastuximab Tesirine Combo Demonstrates Early Efficacy in R/R DLBCL
The safety profile of loncastuximab tesirine plus glofitamab was consistent with the known profiles of the individual agents.
Rare Primary ALK-Positive Anaplastic Large Cell Lymphoma of the Central Nervous System
Anaplastic large cell lymphoma is a rapidly growing and aggressive hematological malignancy. This case highlights the rarity of isolated intradural extramedullary manifestations in the pediatric population.